Member Info for researcher1

good counters folks, and i totally get the sbtx and pbx value approach (i'm in both), but i don't trust soh not to sell too early to pay his wages. my key concern though, after talking to the weight-loss drug expert, is the rapid development of those products - especially into easily affordable oral tablets and micro-dosing '****tails', delivering weight control and additional health benefits (anti alzheimers for a start...). there will still be a place for products like slimbiome, but it's not a big enough place to pay soh's salary....

To clarify - the share sale was worth £20K (£19.5K to be precise) at 17.5p (my average was 22), and all £19 is going into SBTX....

I've been a big OPTI fan (despite the management), but last week sold the last 20K shares in my 'bottom drawer' - why, because I had a long chat with a mounjaro specialist, who convinced me that products such as Slimbiome will only be relevant for another two years AT MOST. Hence I took a not insignificant loss (circa £7K) on the basis that the 'bottom drawer' policy would probably wipe out all remaining value. It's obviously only IMO but I found his arguments very persuasive - not least regarding convenience, transport cost, and the prospect for mounjaro and wegovy to become way cheaper (per dose) than OPTI's products in future. Tomorrow I'm moving the resulting lump sum into SBTX, in anticipation of Zenakine sales figures.... we'll see.....GLA

At what price? 6 p?

Could touch it’s lowest point today - usual AN nonsense to entice desperate shareholders into speculation- but cash raise by September….

Scinv you are an incredibly dull person 😔😔😔😔😔😔😔😔

That's a much more exciting presentation than we thought it would be - early sales figures, broker upgrades (perhaps soon) and raised revenue forecasts by the summer, with no immediate acquisitions and no fundraising!! bought some more during the session....

Well let's see if you are right Fonz - US investors may well show interest, but the trial results are what's going to blow the roof off...

You are right moon, this news will certainly build momentum - but of course the trial results are the game-changer - and as they approach there could be a FOMO stampede...

SA has many limitations, and I agree with Glancy's comments - but the scale of this opportunity trumps his poor understanding of the market....IMO

Have you checked Croda's reputation, and global reach? - and of course the spec on Zenakine is world-leading...

Bazz, SA is a bit naive (and he still doesn't understand AIM), but what he delivered yesterday (finally), as promised, is a company-changing moment - revenues will be unlike anything the company has seen before....

Don't panic, it's going to sell billions, and as I say, no tariffs :-)

Simple answer - it's weak company with a weak muppet of a CEO

A revolutionary product, state-of-the-art skin care, marketed worldwide by a tariff-free company! what's not to like?? - strong buy, before the sales figures start coming in....

BOJO I'm hoping for 20p actually (or 19 at least), but as mia points out, a chunky upfront payment should be demanded by the BoD, and depending on the level of that, the SP could race up from there and never come back (and remember there are other strings to the Scancell bow...)

They've done that repeatedly Rocket - it's all smoke and mirrors - and we know exactly where they are blowing the smoke....

The shares I have in my ISA, which were triple-bagging, are now back level, which feels like a waste of 5 years....however I see this as a huge buying opportunity - the SP by Xmas will be a revelation, IMO....

Under 9p again?

I don't think he can change the narrative of all those attributes you list Fever - the most despised CEO on AIM, by far. Parsortix may sort itself out, but not with his help....

that said, I bought more today 😁